Non-alcoholic fatty liver disease
Conditions
Interventions
administration of sitagliptin (50mg daily)
Sponsors
Iwasaki Naika Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a. The ultrasonographic-proven nonalcoholic fatty liver disease (NAFLD) patient will be evaluated in this study. b. All patients gave their written informed consent to participation in the study.
Exclusion criteria
Exclusion criteria: a.The criteria for exclusion from participation in the study: history of hepatic disease, such as chronic hepatitis C or concurrent active hepatitis B (serum positive for hepatitis B surface antigen), autoimmune hepatitis, primary biliary cirrhosis (PBC), sclerosing cholangitis, hemochromatosis, alpha1-antitrypsin deficiency, Wilsons disease, and current or past consumption of more than 20 g of alcohol daily. b. None of the patients had any clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, or elevated serum bilirubin level to more than twofold the upper limit of normal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Before and after 6 months of sitagliptin (50mg daily) to nonalcoholic fatty liver disease (NAFLD) patients, we assessed hepatic transaminase and ultrasonographic features | — |
Countries
Japan
Contacts
Public ContactTomoyuki Iwasaki
Iwasaki Naika Clinic Endocrinology and Metabolism
Outcome results
None listed